MetaStat IncOver The Counter Market:MTST
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0001
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MetaStat Inc | 590.0 | 0.0x | --- |
Stromacel Inc | 10.0 | 0.0x | --- |
Cell Kinetics Ltd | 2.0K | 0.0x | --- |
BioSyntech Inc | 120.0 | 0.0x | --- |
Nanobac Pharmaceuticals Inc | 250.0 | 0.0x | --- |
ARYx Therapeutics Inc | 30.0 | 0.0x | --- |
Company Information
MetaStat, Inc. is a precision medicine company. The Company's therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. The Company's product development programs are focused on developing drug candidates and companion diagnostic tests that target the MENA pathway. Its pipelines include MENA Diagnostic Assay and MetaSite Breast Assay. The MENA diagnostic assay is a tissue-based quantitative immunofluorescence (QIF) test that measures expression of the pro-metastatic MENA protein splice-variant which is associated with poor outcomes and metastasis in early-stage breast cancer (ESBC) and squamous cell carcinoma of the Lung. MetaSite Breast is an immunohistochemistry test (IHC) that measures micro-anatomical intravasation sites (TMEM) at blood vessels within the tumor microenvironment which are clinically validated as prognostic markers of metastasis in hormone receptor-positive (HR+) ESBC.
Contact Information
- Headquarters
- 27 Drydock Ave., 2Nd FloorBOSTON, MA, United States 02210
- Phone
- 212-796-8170
- Fax
- ---
Executives
- Chairman of the Board
- Jerome Zeldis
- President, Chief Executive Officer, Director
- Douglas Hamilton
- Vice President - Finance
- Daniel Schneiderman
- Director
- Paul Billings
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $590.00 |
|---|---|
Revenue (TTM) | $23.3K |
Shares Outstanding | 5.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.59 |
Book Value | $-0.26 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -15,238.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
